Cinda Biologics (01801.HK) received an increase in holdings of 497,800 shares from JPMorgan Chase

2026-03-27 22:27:02

Gelonghui, March 24丨According to the latest equity disclosure information from the Hong Kong Stock Exchange, on March 19, 2026, Innovent Biologics (01801.HK) was increased by JPMorgan Chase & Co. by 497,800 shares at an average price of HKD 82.2756 per share, involving an investment of approximately HKD 40.9587 million.

After the increase, JPMorgan Chase & Co.'s latest holdings amount to 87,249,700 shares, with the holding ratio rising from 4.99% to 5.02%.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes